Alice Soragni*

Websites:

Posts on Bluesky @soragnilab
Soragni Lab Website

Publications:

Zhao H, Park YM, Zheng Y, Mao Q, Collet C, Hu B, Zhou T, Lin L, Wong S, Pan Y, Monreal AV, Sinha UK, Sedghizadeh P, Soragni A, Lin DC. Genetically Defined Organoid Models Reveal Mechanisms Driving Squamous Cell Neoplastic Evolution and Identify Potential Therapeutic Vulnerabilities. bioRxiv. 2025 Jan 22. view on PubMed

Iyer R, Deshpande A, Pedgaonkar A, Bala PA, Kim T, Brien GL, Finlay D, Vuori K, Soragni A, Murad R, Deshpande AJ. SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs Sarcomagenesis. bioRxiv. 2024 Sep 25. view on PubMed

Al Shihabi A, Tebon PJ, Nguyen HTL, Chantharasamee J, Sartini S, Davarifar A, Jensen AY, Diaz-Infante M, Cox H, Gonzalez AE, Norris S, Sperry J, Nakashima J, Tavanaie N, Winata H, Fitz-Gibbon ST, Yamaguchi TN, Jeong JH, Dry S, Singh AS, Chmielowski B, Crompton JG, Kalbasi AK, Eilber FC, Hornicek F, Bernthal NM, Nelson SD, Boutros PC, Federman NC, Yanagawa J, Soragni A. The landscape of drug sensitivity and resistance in sarcoma. Cell Stem Cell. 2024 Oct 03; 31(10):1524-1542.e4. view on PubMed

Sartini S, Omholt L, Moatamed NA, Soragni A. Mutant p53 Misfolding and Aggregation Precedes Transformation into High-Grade Serous Ovarian Carcinoma. bioRxiv. 2024 Sep 18. view on PubMed

Metts JL, Aye JM, Crane JN, Oberoi S, Balis FM, Bhatia S, Bona K, Carleton B, Dasgupta R, Dela Cruz FS, Greenzang KA, Kaufman JL, Linardic CM, Parsons SK, Robertson-Tessi M, Rudzinski ER, Soragni A, Stewart E, Weigel BJ, Wolden SL, Weiss AR, Venkatramani R, Heske CM. Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials. Cancer. 2024 Nov 15; 130(22):3785-3796. view on PubMed

Nguyen HTL, Kohl E, Bade J, Eng SE, Tosevska A, Al Shihabi A, Tebon PJ, Hong JJ, Dry S, Boutros PC, Panossian A, Gosline SJC, Soragni A. A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening. Cell Rep Methods. 2024 May 20; 4(5):100772. view on PubMed

Gigon L, Müller P, Haenni B, Iacovache I, Barbo M, Gosheva G, Yousefi S, Soragni A, von Ballmoos C, Zuber B, Simon HU. Membrane damage by MBP-1 is mediated by pore formation and amplified by mtDNA. Cell Rep. 2024 04 23; 43(4):114084. view on PubMed

Tebon PJ, Wang B, Markowitz AL, Davarifar A, Tsai BL, Krawczuk P, Gonzalez AE, Sartini S, Murray GF, Nguyen HTL, Tavanaie N, Nguyen TL, Boutros PC, Teitell MA, Soragni A. Drug screening at single-organoid resolution via bioprinting and interferometry. Nat Commun. 2023 06 06; 14(1):3168. view on PubMed

Zhao Z, Chen X, Dowbaj AM, Sljukic A, Bratlie K, Lin L, Fong ELS, Balachander GM, Chen Z, Soragni A, Huch M, Zeng YA, Wang Q, Yu H. Organoids. Nat Rev Methods Primers. 2022; 2. view on PubMed

Al Shihabi A, Davarifar A, Nguyen HTL, Tavanaie N, Nelson SD, Yanagawa J, Federman N, Bernthal N, Hornicek F, Soragni A. Personalized chordoma organoids for drug discovery studies. Sci Adv. 2022 02 18; 8(7):eabl3674. view on PubMed

Sartini S, Soragni A. Cervical organoids go viral. Cell Stem Cell. 2021 08 05; 28(8):1337-1338. view on PubMed

Nguyen HTL, Soragni A. Patient-Derived Tumor Organoid Rings for Histologic Characterization and High-Throughput Screening. STAR Protoc. 2020 09 18; 1(2). view on PubMed

Soragni A, Maitra A. Of scientists and tweets. Nat Rev Cancer. 2019 09; 19(9):479-480. view on PubMed

Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, Huang J, Memarzadeh S, Damoiseaux R, Soragni A. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol. 2019; 2:78. view on PubMed

Avasthi P, Soragni A, Bembenek JN. Journal clubs in the time of preprints. Elife. 2018 06 11; 7. view on PubMed

Soragni A, Janzen DM, Johnson LM, Lindgren AG, Thai-Quynh Nguyen A, Tiourin E, Soriaga AB, Lu J, Jiang L, Faull KF, Pellegrini M, Memarzadeh S, Eisenberg DS. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell. 2016 Jan 11; 29(1):90-103. view on PubMed

Soragni A, Yousefi S, Stoeckle C, Soriaga AB, Sawaya MR, Kozlowski E, Schmid I, Radonjic-Hoesli S, Boutet S, Williams GJ, Messerschmidt M, Seibert MM, Cascio D, Zatsepin NA, Burghammer M, Riekel C, Colletier JP, Riek R, Eisenberg DS, Simon HU. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell. 2015 Mar 19; 57(6):1011-1021. view on PubMed

Ries J, Udayar V, Soragni A, Hornemann S, Nilsson KP, Riek R, Hock C, Ewers H, Aguzzi AA, Rajendran L. Superresolution imaging of amyloid fibrils with binding-activated probes. ACS Chem Neurosci. 2013 Jul 17; 4(7):1057-61. view on PubMed

Rabe M, Soragni A, Reynolds NP, Verdes D, Liverani E, Riek R, Seeger S. On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms. ACS Chem Neurosci. 2013 Mar 20; 4(3):408-17. view on PubMed

Reynolds NP, Soragni A, Rabe M, Verdes D, Liverani E, Handschin S, Riek R, Seeger S. Mechanism of membrane interaction and disruption by α-synuclein. J Am Chem Soc. 2011 Dec 07; 133(48):19366-75. view on PubMed

Schütz AK, Soragni A, Hornemann S, Aguzzi A, Ernst M, Böckmann A, Meier BH. The amyloid-Congo red interface at atomic resolution. Angew Chem Int Ed Engl. 2011 Jun 20; 50(26):5956-60. view on PubMed

Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011 Mar 08; 108(10):4194-9. view on PubMed

Wasmer C, Zimmer A, Sabaté R, Soragni A, Saupe SJ, Ritter C, Meier BH. Structural similarity between the prion domain of HET-s and a homologue can explain amyloid cross-seeding in spite of limited sequence identity. J Mol Biol. 2010 Sep 17; 402(2):311-25. view on PubMed

Greenwald J, Buhtz C, Ritter C, Kwiatkowski W, Choe S, Maddelein ML, Ness F, Cescau S, Soragni A, Leitz D, Saupe SJ, Riek R. The mechanism of prion inhibition by HET-S. Mol Cell. 2010 Jun 25; 38(6):889-99. view on PubMed

Lange A, Gattin Z, Van Melckebeke H, Wasmer C, Soragni A, van Gunsteren WF, Meier BH. A combined solid-state NMR and MD characterization of the stability and dynamics of the HET-s(218-289) prion in its amyloid conformation. Chembiochem. 2009 Jul 06; 10(10):1657-65. view on PubMed

Soragni A, Zambelli B, Mukrasch MD, Biernat J, Jeganathan S, Griesinger C, Ciurli S, Mandelkow E, Zweckstetter M. Structural characterization of binding of Cu(II) to tau protein. Biochemistry. 2008 Oct 14; 47(41):10841-51. view on PubMed

Wasmer C, Soragni A, Sabaté R, Lange A, Riek R, Meier BH. Infectious and noninfectious amyloids of the HET-s(218-289) prion have different NMR spectra. Angew Chem Int Ed Engl. 2008; 47(31):5839-41. view on PubMed

Aachmann FL, Fomenko DE, Soragni A, Gladyshev VN, Dikiy A. Solution structure of selenoprotein W and NMR analysis of its interaction with 14-3-3 proteins. J Biol Chem. 2007 Dec 21; 282(51):37036-44. view on PubMed

Delany I, Ieva R, Soragni A, Hilleringmann M, Rappuoli R, Scarlato V. In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in Helicobacter pylori. J Bacteriol. 2005 Nov; 187(22):7703-15. view on PubMed